1
|
|
2
|
|
3
|
Gallamini A, Hutchings M, Borra A. Functional Imaging in Hodgkin Lymphoma. HODGKIN LYMPHOMA 2015. [DOI: 10.1007/978-3-319-12505-3_7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
4
|
Gawande RS, Khurana A, Messing S, Zhang D, Castañeda RT, Goldsby RE, Hawkins RA, Daldrup-Link HE. Differentiation of normal thymus from anterior mediastinal lymphoma and lymphoma recurrence at pediatric PET/CT. Radiology 2011; 262:613-22. [PMID: 22157202 DOI: 10.1148/radiol.11110715] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
PURPOSE To evaluate the role of positron emission tomography (PET)/computed tomography (CT) in the differentiation of normal thymus from mediastinal lymphoma and lymphoma recurrence in pediatric patients. MATERIALS AND METHODS The study was approved by the institutional review board, and informed consent was waived. The study was HIPAA compliant. Two hundred eighty-two fluorine 18 fluorodeoxyglucose PET/CT studies in 75 pediatric oncology patients were reviewed retrospectively. Patients were divided into four groups: anterior mediastinal lymphoma (group A, n=16), anterior mediastinal lymphoma with subsequent recurrence (group B, n=5), lymphoma outside the mediastinum (group C, n=16), and other malignant tumors outside the thymus (group D, n=38). Analyses included measurements of the maximum anteroposterior and transverse dimensions of the anterior mediastinal mass or thymus on axial CT images and measurements of maximum standardized uptake values of anterior mediastinal mass, thymus (SUVt), and bone marrow at the level of the fifth lumbar vertebra (SUVb) on PET images. Quantitative parameters were compared by using an analysis of variance test. RESULTS Mean prechemotherapy SUVt was 4.82 for group A, 8.45 for group B, 2.00 for group C, and 2.09 for group D. Mean postchemotherapy SUVt for group B was 4.74. Thymic rebound (mean SUVt, 2.89) was seen in 44% of patients at a mean interval of 10 months from the end of chemotherapy. The differences between prechemotherapy SUVt of mediastinal lymphoma and normal thymus and postchemotherapy SUVt of lymphoma recurrence and thymic rebound were highly significant (P<.001). CONCLUSION SUVt is a sensitive predictor for differentiation of normal thymus or thymic rebound from mediastinal lymphoma. SUVt of 3.4 or higher is a strong predictor of mediastinal lymphoma.
Collapse
Affiliation(s)
- Rakhee S Gawande
- Department of Radiology, Stanford University School of Medicine, and Pediatric Radiology Section, Lucile Packard Children's Hospital, 725 Welch Rd, Stanford, CA 94305-5654, USA
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Banwait R, O'Regan K, Campigotto F, Harris B, Yarar D, Bagshaw M, Leleu X, Leduc R, Ramaiya N, Weller E, Ghobrial IM. The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. Am J Hematol 2011; 86:567-72. [PMID: 21681781 DOI: 10.1002/ajh.22044] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Disease assessment in WM is dependent on the quantification of the IgM monoclonal protein and percent involvement of the bone marrow. There is a need for imaging studies that objectively measure tumor load in these patients. In this study, we sought to examine the role of combined FDG-PET/CT imaging in the detection of tumor load and in the assessment of response to therapy. Thirty-five patients were enrolled on a prospective study using bortezomib and rituximab therapy and were included in this study because they completed a pre- and post-treatment FDG-PET/CT imaging at one facility (12 newly diagnosed and 23 relapsed/refractory). The use of combined FDG-PET/CT imaging showed positive findings in 83% of patients with WM, unlike prior studies using conventional imaging that indicate that only 20% of patients have lymphadenopathy or hepatosplenomegaly. Moreover, 43% of patients had abnormal bone marrow uptake on FDG-PET imaging that can potentially help in the assessment of their tumor load, especially with heterogenous sampling of the bone marrow. There was no statistical correlation between EORTC response criteria for FDG-PET/CT and response by monoclonal protein. This is the first study to examine the role of FDG-PET/CT imaging in WM. Future studies should examine the role of FDG-PET/CT in conjunction with monoclonal protein response in the assessment of progression-free survival in patients with WM.
Collapse
Affiliation(s)
- Ranjit Banwait
- Dana-Farber Cancer Institute, Medical oncology, Harvard Medical School, Boston, MA, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Hicks RJ. The evolving role of fluorodeoxyglucose positron emission tomography (FDG PET) in lymphoma: How do we reconcile conflicting results in the era of evidence-based medicine? Leuk Lymphoma 2009; 47:2008-10. [PMID: 17071468 DOI: 10.1080/10428190600758611] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- Rodney J Hicks
- Peter MacCallum Cancer Centre, Melbourne, VIC, 3002, Australia.
| |
Collapse
|
7
|
Abstract
PET has become a cornerstone procedure in modern lymphoma management. This paper reviews, from a clinical point of view, the evidence for using PET in the different subtypes of lymphoma and the different steps of their management. The reader is given an overview of the current PET-based interventional lymphoma trials and an insight into possible future developments in the field, including new PET tracers.
Collapse
Affiliation(s)
- Martin Hutchings
- Departments of Oncology and Haematology, Rigshospitalet, The Finsen Centre-Copenhagen University Hospital, 9 Blegdamsvej, Copenhagen Ø, Denmark.
| |
Collapse
|
8
|
Allen-Auerbach M, de Vos S, Czernin J. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients. Radiol Clin North Am 2008; 46:199-211, vii. [PMID: 18619376 DOI: 10.1016/j.rcl.2008.03.004] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Fully diagnostic positron emission tomography (PET)/CT scans acquired during oral and intravenous contrast can be provided to patients and referring physicians in a single imaging session. Although FDG uptake varies, most low-grade lymphomas exhibit sufficient FDG avidity to also be staged reliably with FDG PET/CT. PET/CT imaging is more accurate for lymphoma staging than PET or CT alone and has substantial impact on patient management. This accurate whole-body glucose metabolic survey should serve as the baseline for subsequent treatment response evaluations. PET/CT has evolved to become the modality of choice for staging of nodal and extranodal lymphoma, for assessing therapeutic response, and for establishing patient prognosis.
Collapse
Affiliation(s)
- Martin Allen-Auerbach
- Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center/Nuclear Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095-6948, USA
| | | | | |
Collapse
|
9
|
|
10
|
Mohile NA, Deangelis LM, Abrey LE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol 2008; 10:223-8. [PMID: 18287338 DOI: 10.1215/15228517-2007-061] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
(18)F-Fluorodeoxyglucose (FDG) PET has become an important tool in the management of non-Hodgkin's lymphoma (NHL), but its role in the evaluation of primary CNS lymphoma (PCNSL) has not been established. We investigated the ability of body FDG PET to detect systemic disease in the staging and restaging of PCNSL. The records of 166 PCNSL patients seen at Memorial Sloan-Kettering Cancer Center were examined. Forty-nine patients who underwent body FDG PET for staging of PCNSL were identified. Clinical data were reviewed to determine FDG PET results and their influence on therapy. Body FDG PET disclosed a systemic site of malignancy in 15% of patients. NHL was found in 11% of all patients, 7% of patients at diagnosis, and 27% of patients at CNS relapse. Four percent had a second systemic neoplasm. Workup with conventional staging did not reveal systemic disease, and in 8% of patients, body FDG PET was the only abnormal diagnostic exam suggestive of lymphoma. FDG PET findings altered patient treatment and resulted in additional chemotherapy, surgery, or radiotherapy. Our findings suggest that FDG PET may be more sensitive than conventional body staging and may disclose higher rates of concomitant systemic disease at PCNSL diagnosis. Body FDG PET may be an important noninvasive adjunct to conventional PCNSL staging, and its utility should be evaluated prospectively.
Collapse
Affiliation(s)
- Nimish A Mohile
- Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
| | | | | |
Collapse
|
11
|
Specht L. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas. Semin Radiat Oncol 2007; 17:190-7. [PMID: 17591566 DOI: 10.1016/j.semradonc.2007.02.005] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
2-[18F]fluoro-2-deoxyglucose positron-emission tomography (FDG-PET) is used increasingly in the clinical management of lymphomas. With regard to staging, FDG-PET is more sensitive and specific than conventional staging methods in FDG avid lymphomas (ie, Hodgkin lymphoma and most aggressive non-Hodgkin lymphomas). Despite methodological problems, in particular the lack of a valid reference test, FDG-PET is approved and generally used for this purpose. With regard to response evaluation, FDG-PET at the end of treatment seems to aid considerably in differentiating between residual masses with or without residual lymphoma. Hence, new revised response criteria have been proposed, incorporating the result of FDG-PET at the end of treatment. An early interim FDG-PET scan after 1 to 3 cycles of chemotherapy is a very strong predictor of outcome, and trials are now in progress testing treatment modifications on this basis. With regard to treatment planning, in the context of combined-modality therapy, radiotherapy for lymphomas is moving toward more conformal techniques reducing the irradiated volume to include only the macroscopic lymphoma. In this situation, accurate imaging is essential, and FDG-PET coregistered with the planning computed tomography (CT) scan is used increasingly. The availability of PET/CT scanners suited for virtual simulation has aided this process. However, clinical data evaluating this technique are at present sparse.
Collapse
Affiliation(s)
- Lena Specht
- Chief Oncologist, Associate Professor of Oncology, Departments of Oncology, Hematology, and Radiation Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark
| |
Collapse
|
12
|
Wong CYO, Thie J, Parling-Lynch KJ, Zakalik D, Wong RH, Gaskill M, Margolis JH, Hill J, Sukari A, Chundru S, Fink-Bennett D, Nagle C. Investigating the Existence of Quantum Metabolic Values in Non-Hodgkin’s Lymphoma by 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography. Mol Imaging Biol 2006; 9:43-9. [PMID: 17176979 DOI: 10.1007/s11307-006-0074-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
OBJECTIVES To investigate the existence of quantum metabolic values in various subtypes of non-Hodgkin's lymphoma (NHL). METHODS Fifty-eight patients with newly diagnosed NHL and positron emission tomography (PET) performed within three months of biopsy were included. The standardized uptake value (SUV) from PET over the area of biopsy and serum glucose [Glc] were recorded. The group glucose sensitivity(G) for indolent and aggressive NHL was obtained by linear regression with ln(SUV) = G x ln[Glc] + C, where C is a constant for the group. Finally, the individual's glucose sensitivity (g) was obtained by g = {ln(SUV)-C}/ln[Glc], along with their means in various subtypes of NHL. To further investigate the influence of extreme [Glc] conditions, the SUVs corrected by the individually calculated g at various glucose levels, [Glc'] using SUV' =SUV x {[Glc']/[Glc]}(g), were compared to the original SUVs for both indolent and aggressive NHL. RESULTS The averaged g (=G) for aggressive was significant different from that for indolent NHL (-0.94 +/- 0.51 vs. +0.13 +/- 0.10, respectively, p < 0.00005). There were significant differences in SUV for [Glc] < 80 or >110 mg/dl for both types of NHL. Unlike overlap among SUVs between NHL subtypes, the g value clearly categorized them into two distinct groups with positive (near-zero) and negative g values (around -1) for the indolent and aggressive NHLs, respectively. CONCLUSIONS Distinct quantum metabolic values of -1 and 0 were noted in NHL. Aggressive NHL has a more negative value (or higher glucose sensitivity) than that of indolent and, thus, is more susceptible to extreme glucose variation.
Collapse
Affiliation(s)
- Ching-yee Oliver Wong
- Positron Diagnostic Center and Cyclotron, Department of Nuclear Medicine, William Beaumont Hospital, 3601 W. Thirteen Mile Road, Royal Oak, MI 48073-6769, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Hernandez-Maraver D, Hernandez-Navarro F, Gomez-Leon N, Coya J, Rodriguez-Vigil B, Madero R, Pinilla I, Martin-Curto LM. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma. Br J Haematol 2006; 135:293-302. [PMID: 17032175 DOI: 10.1111/j.1365-2141.2006.06284.x] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
An accurate initial staging of patients with non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) is critical for the selection of an appropriate treatment. Computed tomography (CT) remains the standard imaging technique, although it is based on anatomic criteria. Positron emission tomography (PET) with 2-deoxy-2-[fluorine-18]fluoro-d-glucose (FDG) provides useful functional information but requires anatomical correlation to localise lesions accurately. We have prospectively compared the accuracy of combined PET/CT with that of CT and PET alone at initial staging in lymphoma patients. Forty-seven newly diagnosed patients were evaluated. PET/CT was superior compared with CT and PET in nodal evaluation and detection of extranodal disease. Using a staging algorithm with PET/CT resulted in the disease stage being increased in 11 of 47 patients (10 NHL and 1 HL) (McNemar test P = 0.012). Therefore, a different treatment strategy based on PET/CT findings was suggested for seven patients (14.8%). PET/CT markedly improves accuracy in the diagnostic work-up of patients with lymphoma.
Collapse
|
14
|
Kumar R, Maillard I, Schuster SJ, Alavi A. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin North Am 2004; 42:1083-100. [PMID: 15488559 DOI: 10.1016/j.rcl.2004.08.008] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
FDG-PET imaging has a number of advantages in the management of patients with lymphoma. PET shows a functional metabolic status and gives quantitative information. In addition, PET provides whole-body images that give a comprehensive assessment of disease extent during the staging and followup. Based on the present literature, FDG-PET is at least equivalent to CT for the initial staging of lymphomas. The impact of new technologies of combined PET/CT and fast-scanning CT with contrast has yet to be evaluated in the management of lymphoma patients, however. At this point, FDG-PET and CT must be considered as giving complementary staging information. FDG-PET also has high diagnostic accuracy for restaging lymphoma after initial treatment. FDG-PET has shown high accuracy in the early prediction of response to chemotherapy and in the evaluation of residual masses after chemotherapy or radiation therapy. Therefore, PET is likely to play a major role in tailoring the intensity of the treatment to the individual patient. A pretreatment FDG-PET study is essential for accurate assessment of residual masses and early monitoring of response to the treatment. In addition, a baseline PET scan will help detect relapse or residual disease, because relapse occurs most often in the region of previous disease.
Collapse
Affiliation(s)
- Rakesh Kumar
- Division of Nuclear Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, 110 Donner Building, Philadelphia, PA 19104, USA
| | | | | | | |
Collapse
|
15
|
Hutchings M, Eigtved AI, Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hematol 2004; 52:19-32. [PMID: 15363464 DOI: 10.1016/j.critrevonc.2004.05.007] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/28/2004] [Indexed: 11/19/2022] Open
Abstract
Positron emission tomography (PET) is a molecular functional imaging technique that provides qualitative and quantitative information about the localization and activity of pathophysiological processes. The most commonly used tracer for oncological purposes is 2-[18F]fluoro-2-deoxy-d-glucose (FDG). FDG-PET has within recent years become the most important nuclear medicine imaging modality in the management of lymphoma. This review summarizes the data published so far concerning the value of FDG-PET in staging, treatment monitoring, therapy planning, and follow-up of Hodgkin lymphoma (HL). FDG-PET detects more disease sites and involved organs than conventional staging procedures including computerized tomography (CT) and has a large influence on staging. FDG-PET during and after therapy appears to provide considerable prognostic information. However, the impact on patient outcome is not clear since no controlled trials are conducted and follow-up periods are generally short. The value of dual-modality PET/CT and its potential role in the radiotherapy planning is discussed.
Collapse
Affiliation(s)
- Martin Hutchings
- PET and Cyclotron Unit, Department of Clinical Physiology and Nuclear Medicine, Centre of Diagnostic Investigations, Rigshospitalet KF-3982, Copenhagen University Hospital, 9, Blegdamsvej, DK-2100 Copenhagen, Denmark
| | | | | |
Collapse
|
16
|
Foo SS, Mitchell PL, Berlangieri SU, Smith CL, Scott AM. Positron emission tomography scanning in the assessment of patients with lymphoma. Intern Med J 2004; 34:388-97. [PMID: 15271172 DOI: 10.1111/j.1445-5994.2004.00614.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND The detection of lymphoma by computed tomography (CT) scanning is known to be improved by positron emission tomography (PET) and/or gallium scanning, although the direct comparative accuracy of these imaging modalities remains a subject of ongoing review. AIMS The aim of the present study was to compare PET scanning with conventional imaging (CT and/or gallium scanning) in patients with lymphoma. METHODS A retrospective study of 38 patients (25 men; 13 women; median age 39.5 years; range 18.0-81.0 years) who had had PET scans (24 scans at initial staging and 46 scans at restaging, including suspected disease relapse) was carried out. Thirty-one concurrent gallium scans had been performed. Disease was validated with clinical follow up or biopsy. RESULTS The sensitivities of PET and CT at initial staging were 96 and 71%, respectively. PET identified additional sites of disease compared with CT in 29% of patients. Of the 15 patients who had had all three imaging modalities, the sensitivities of PET, CT and gallium were 93, 67 and 87%, respectively. At treatment completion, the positive predictive values of PET, CT and gallium scans for relapse given a residual mass were 100, 33 and 0%, respectively (P = 0.006 for PET and CT comparison). The negative predictive values of PET, CT and gallium were 76, 0 and 70%, respectively (P-value not significant). In suspected disease relapse, PET results changed management in 50% of patients. CONCLUSION Compared with CT and gallium scans, PET has superior accuracy in staging and restaging, and its greatest value lies in its positive predictive value for relapse in patients with residual masses.
Collapse
Affiliation(s)
- S S Foo
- Department of Medical Oncology, Ludwig Institute for Cancer Research, University of Melbourne, Austin Hospital, Melbourne, Victoria, Australia.
| | | | | | | | | |
Collapse
|
17
|
Abstract
Positron emission tomography (PET) is a novel functional imaging technique that provides several inherent advantages over conventional nuclear scintigraphy. Several studies have suggested a role for PET using the positron emitter fluorine-18 in the diagnosis and follow-up of patients with lymphoma. This review summarizes the existing data evaluating the role of 2-fluoro-2-deoxy-D-glucose (FDG)-PET in both the staging and follow-up of patients with lymphoma. Most studies of PET involve patients with either Hodgkin's disease or diffuse large B-cell non-Hodgkin's lymphoma. PET detects more disease sites above and below the diaphragm on staging of lymphoma than gallium scintigraphy and may have particular utility in the evaluation of the spleen. Moreover, persistently positive PET scans during and after chemotherapy appear to have a high sensitivity for predicting subsequent relapse. A negative PET scan at the end of therapy provides very favorable prognostic information. Persistently positive PET scans at the end of therapy warrant close follow-up or additional diagnostic procedures, since some of those patients may remain in prolonged remission. Clearly, additional studies, including prospective blinded trials and cost-effectiveness analyses, are warranted to determine which subsets of patients with lymphoma ultimately will benefit from this modality.
Collapse
Affiliation(s)
- Jonathan W Friedberg
- Lymphoma Program, James P. Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA.
| | | |
Collapse
|
18
|
Koga H, Matsuo Y, Sasaki M, Nakagawa M, Kaneko K, Hayashi K, Kuwabara Y, Honda H. Differential FDG accumulation associated with GLUT-1 expression in a patient with lymphoma. Ann Nucl Med 2003; 17:327-31. [PMID: 12932118 DOI: 10.1007/bf02988530] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
We herein report a case of malignant lymphoma that showed differential FDG accumulation associated with the degree of glucose transporter 1 (GLUT-1) expression. For clinical staging purpose, FDG-PET was performed on a 47-year-old male who had been diagnosed to have malignant lymphoma, diffuse medium B-cell type. Although an X-ray CT showed multiple and bulky lymphadenopathy including bilateral submandibular, deep cervical, supraclavicular, axillar, hilar, mesenteric and paraaortic regions, FDG-PET showed a high accumulation only in the bilateral submandibular and deep cervical region. An immunohistochemical analysis demonstrated a high GLUT-1 expression in the right cervical lymph node, which showed a high FDG uptake. On the other hand, a bone marrow specimen with diffuse lymphoma cell involvement indicated showed no FDG accumulation and also revealed a negative GLUT-1 expression. This case suggests that the differential FDG accumulation shown by lesions is associated with the degree of GLUT-1 expression in patients with lymphoma.
Collapse
Affiliation(s)
- Hirofumi Koga
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Sasaki M, Kuwabara Y, Koga H, Nakagawa M, Chen T, Kaneko K, Hayashi K, Nakamura K, Masuda K. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med 2002; 16:337-45. [PMID: 12230093 DOI: 10.1007/bf02988618] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
OBJECTIVES The aim of this study is to evaluate the clinical impact of whole-body FDG-PET for the pre-therapeutic evaluation of malignant lymphoma and compared to that of 67Ga-scintigraphy when added to non-RI examinations. METHODS We examined 46 patients with malignant lymphoma including 42 newly diagnosed cases and 4 relapsed cases. Whole-body FDG-PET was started 63 minutes after the administration of FDG with ECAT EXACT HR+. The clinical stage of each patient was determined based on the results of a non-RI examination (consisting of physical examination, CT, gastrointestinal studies and bone marrow aspiration), 67Ga planar images and FDG-PET. Discrepant findings were verified based on the response to treatment and the findings of a follow-up examination more than 6 months after treatment. Finally, 152 nodal regions and 19 extranodal tissues were found to be involved by disease. RESULTS In the 152 nodal lesions, FDG-PET detected 54 nodal lesions in addition to 98 lesions detected by non-RI examinations, whereas 67Ga-scintigraphy detected 14 additional lesions. The sensitivity of non-RI, non-RI + 67Ga and non-RI + FDG was 64.5%, 73.7% and 100.0%, respectively. In 19 extranodal lesions, FDG-PET detected 5 extranodal lesions in addition to 13 lesions detected by non-RI examinations, whereas 67Ga-scintigraphy detected 1 additional lesion. The sensitivity of non-RI, non-RI + 67Ga and non-RI + FDG was 68.4%, 73.7% and 94.7%, respectively. When combining the FDG-PET findings with the non-RI findings, the improvement of the detectability was much higher than that when 67Ga findings were combined to the non-RI findings. For the staging of lymphoma, the non-RI and non-RI + 67Ga findings accurately diagnosed 76.1% and 80.4%, respectively, whereas the non-RI + FDG findings accurately diagnosed 82.6%. Finally, FDG-PET resulted in changes in the clinical management of 8 patients (17.4%). CONCLUSIONS FDG-PET offers more information in addition to the findings of conventional diagnostic methods than 67Ga-scintigraphy in order to accurately detect malignant lymphoma. FDG-PET can therefore play an important role in therapeutic decision making on lymphoma.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Citrates
- Decision Making
- Female
- Fluorodeoxyglucose F18
- Gallium
- Hodgkin Disease/classification
- Hodgkin Disease/diagnostic imaging
- Hodgkin Disease/pathology
- Hodgkin Disease/therapy
- Humans
- Lymphoma/diagnostic imaging
- Lymphoma, Non-Hodgkin/classification
- Lymphoma, Non-Hodgkin/diagnostic imaging
- Lymphoma, Non-Hodgkin/pathology
- Lymphoma, Non-Hodgkin/therapy
- Male
- Middle Aged
- Neoplasm Recurrence, Local/classification
- Neoplasm Recurrence, Local/diagnostic imaging
- Neoplasm Recurrence, Local/pathology
- Neoplasm Recurrence, Local/therapy
- Neoplasm Staging/methods
- Patient Care Management/methods
- Radiopharmaceuticals
- Reproducibility of Results
- Sensitivity and Specificity
- Tomography, Emission-Computed/methods
- Treatment Outcome
- Whole-Body Counting/methods
Collapse
Affiliation(s)
- Masayuki Sasaki
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Borrego Dorado I, Vázquez Albertino R. [A proposal for the rational use of the PET in oncology]. REVISTA ESPANOLA DE MEDICINA NUCLEAR 2002; 21:163-73. [PMID: 12206749 DOI: 10.1016/s0212-6982(02)72056-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE This study aims to develop a Clinical Practice Guide for the rational use of the Positron Emission Tomography (PET) in Oncology, that makes it possible to approach the real existence of demand in the public health care service of Andalucía, by limiting the clinical indications, using criteria based on the existence of sufficient scientific evidence on the effectiveness and clinical impact of PET. METHOD The consensus technique was used to elaborate the Guide, gathering a group of nuclear medicine experts. Prior to this a systematic research of the scientific literature was carried out, using strict criteria for the selection of the articles, such as the evaluation of the epidemiological data, work methodology, clinical and pathological diagnosis, gold standard references and statistical analysis. In each pathology group, the existence of alternative non-invasive diagnostic techniques was assessed, comparing its effectiveness and clinical impact with the PET, and the existence of useful treatments correlated with the results of the examination was also evaluated. When it was possible, we evaluated the cost-effectiveness of the PET. Finally, the cost-effectivity of the technique was assessed and the limitation of present and future resources and the economical costs arising from the PET costs and introduction were evaluated. RESULTS AND CONCLUSIONS It was considered that the PET was indicated in the following clinical conditions: 1: Assessment of Colorectal Cancer recurrence in patients with increased levels of tumor markers and negative morphological imaging techniques. Suspicion of isolated resectable recurrence. 2: Restaging in patients with high risk melanoma. 3: Differential diagnosis of solitary pulmonary nodules. 4: Staging of non-small cell bronchial carcinoma. 5: Staging and detection of recurrences of lymphomas. 6: Restaging of head and neck cancer with possibilities of curative treatment. 7: Diagnosis of recurrences in differentiated thyroid cancer in patients with increased plasma levels of thyroglobulin and negative radioiodine scintiscan. 8: Staging and follow-up of medullary thyroid carcinoma. 9: Differential diagnosis between recurrent tumor and scar or radionecrosis in brain tumors.
Collapse
Affiliation(s)
- I Borrego Dorado
- Unidad de Diagnóstico de Medicina Nuclear, Hospitales Universitarios Virgen del Rocío, Sevilla.
| | | |
Collapse
|
21
|
Hustinx R, Bénard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 2002; 32:35-46. [PMID: 11839068 DOI: 10.1053/snuc.2002.29272] [Citation(s) in RCA: 159] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging is increasingly used for the management of patients with cancer. The technique is now well accepted by most physicians as an effective complement to the existing imaging modalities. For many malignancies, PET achieves high sensitivity and specificity. The critical role of this powerful technique is realized increasingly in the day-to-day practice of oncology. This is particularly true for the management of patients with non-small-cell lung cancer (NSCLC). The contribution of PET for the selection of patients eligible for curative treatments in this setting is well established. Convincing data also exist to support the use of PET for evaluating patients with recurrent colorectal carcinoma, for staging and restaging lymphomas, and for diagnosing recurrent thyroid carcinoma in the presence of elevated thyroglobulin and negative 131I scans. Other indications include staging of various recurrent malignancies, such as breast cancer, melanoma, and head and neck and gynecologic carcinomas. Existing data are limited for the determination of the impact of PET in certain malignancies, and further studies, which should include outcome information, will allow clarification of the role of this modality for such indications. Despite the small number of studies specifically designed to assess changes in management plans for some malignancies after performing PET the overall favorable results are encouraging enough at this time to include this modality as an essential element of the practice of modern oncology. Finally, the evolving role of PET imaging as a predictor of response after local or systemic treatment may add a major dimension to the application of this novel technique.
Collapse
Affiliation(s)
- Roland Hustinx
- Division of Nuclear Medicine, Centre hospitalier universitaire, Liege, Belgium
| | | | | |
Collapse
|
22
|
Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, Franke WG, Ehninger G. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115:793-800. [PMID: 11843811 DOI: 10.1046/j.1365-2141.2001.03147.x] [Citation(s) in RCA: 149] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the assessment of post-treatment residual masses in patients with Hodgkin's disease (HD) or non-Hodgkin's lymphomas (NHL) was evaluated. We prospectively studied 58 patients with HD (n = 43) or NHL (n = 15) who had post-therapeutic complete remission with residual masses (CRu) indicated by computerized tomography. Analysis of 62 residual locations by FDG-PET was performed separately for HD and NHL. Patients with a PET-positive residual mass [standardized uptake value (SUV) > 3] had a recurrence rate of 62.5% (5/8 patients), whereas patients with PET-negative residual mass (SUV < or =3.0) showed a recurrence rate of 4% (2/50 patients, P = 0.004). A positive FDG-PET study correlated with a significantly poorer progression-free survival (P < 0.00001). No recurrence occurred in any of the 39 HD patients with a negative PET scan (negative predictive value, 100%). Four out of four NHL patients with a positive PET study relapsed (positive predictive value, 100%). In conclusion, FDG-PET is a suitable non-invasive method with a high degree of accuracy in the prediction of early recurrence in lymphoma patients with CRu.
Collapse
Affiliation(s)
- R Naumann
- Department of Internal Medicine I, University Hospital Carl Gustav Carus at the Dresden University of Technology, Fetscherstrasse 74, D-01307 Dresden, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Abstract
The applications for FDG-PET imaging are rapidly growing and accepted in the field of oncology. FDG-PET imaging does not replace other imaging modalities, such as CT, but seems to be very helpful in specific situations where CT has known limitations, such as differentiation of benign from malignant indeterminate lesions on CT, differentiation of post-treatment changes versus recurrent tumor, differentiation of benign from malignant lymph nodes, and monitoring therapy. The biggest use of FDG-PET presently is in N and M staging of various body tumors. The addition of FDG-PET in the evaluation of oncologic patients in well-defined algorithms including a combination of imaging studies seems to be cost effective by accurately identifying patients who benefit from invasive procedures and saving unnecessary costly invasive procedures on patients who do not benefit from them. Although PET imaging may decrease the cost of health care by reducing the number of invasive procedures, implementation of clinical PET has been hindered by the high cost of the purchase, operation expenses, and maintenance of PET systems; the need for immediate access to a source of 18F (owing to the 110-minute half-life); and the limited reimbursement for clinical procedures by third-party payers. These combined factors have resulted in the development by manufacturers of hybrid gamma camera systems capable of performing positron imaging. These systems can be used to image conventional radiopharmaceuticals used in general nuclear medicine and positron-emitting radiopharmaceuticals. The performance of these camera-based PET systems has improved markedly over the past few years with the introduction of thicker NaI (T1) crystals, iterative reconstruction algorithms, and attenuation correction. These new developments in medical imaging instrumentation have contributed to the expansion of the number of cyclotrons, and have driven the concept of commercial FDG distribution centers.
Collapse
Affiliation(s)
- D Delbeke
- Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2675, USA
| | | |
Collapse
|
24
|
Abstract
Nuclear medicine imaging techniques allow us to peer into physiologic processes, avoiding the need to wait until anatomic changes are detectable, and allowing for prompt, informed management decisions. Recognition of normal, abnormal, and post-therapy scan patterns is critical to achieve the necessary sensitivity and specificity needed for patient management. Gallium scintigraphy using updated techniques has an important continuing role in management of patients with lymphoma. Gallium scintigraphy can contribute to patient management primarily by detecting residual disease or relapse after treatment, monitoring response during therapy, and providing prognostic information. FDG and PET cameras, especially dedicated ring systems, offer high resolution and high-contrast images, thereby demonstrating additional sites of disease. Although preliminary evidence looks promising that FDG can provide all information that Ga-67 has been shown to do in the past, additional data are required. Further studies will show whether FDG-PET can provide prognostic information and predict disease-free and overall survival, the availability of both FDG and PET scanners, and issues of cost. Patient accessibility will undoubtedly also play a role in when, or whether, FDG-PET will totally replace Ga-67 scintigraphy in the management of patients with lymphoma.
Collapse
Affiliation(s)
- P K Rehm
- Division of Nuclear Medicine, University of Virginia Health System, Charlottesville, 22908, USA
| |
Collapse
|
25
|
Alavi A, Sam JW, Zhuang H. PET Imaging in Oncologic Patients. J Vasc Interv Radiol 2001. [DOI: 10.1016/s1051-0443(01)70116-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|